4593.T
The company operates in the biotechnology and medical research sector, focusing on pharmaceuticals and medical research, and generates revenue primarily through the development and commercialization of biopharmaceutical products.
Business. 4593.T is a biotechnology and medical research company operating within the healthcare sector. The firm generates revenue through product sales, focusing on pharmaceuticals and medical research activities. Specific details regarding its operating segments, headquarters location, and primary stock exchange listing are not provided in the available data. Consequently, the company is described at the industry level without geographic or segment-specific breakdowns.
Analyst recommendations
7 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
4593.T is a biotechnology and medical research company operating within the healthcare sector. The firm generates revenue through product sales, focusing on pharmaceuticals and medical research activities. Specific details regarding its operating segments, headquarters location, and primary stock exchange listing are not provided in the available data. Consequently, the company is described at the industry level without geographic or segment-specific breakdowns.
The company's capital structure is characterized by a high debt-to-equity ratio of 1.5, indicating a significant reliance on debt financing. Despite holding JPY 5.68 billion in cash and equivalents, the company's liquidity position is rated as medium due to the negative net cash position after subtracting total debt. The price-to-book ratio of 8.67 suggests that the market is valuing the company's equity at a premium relative to its book value, which may reflect expectations of future growth or intangible assets.
Profitability metrics reveal a challenging financial situation. The company reported a net loss of JPY 2.22 billion, with a return on equity of -45.34% and a return on assets of -13%. These figures are significantly below the industry norms for biotechnology firms, which typically exhibit higher returns due to the high-margin nature of pharmaceutical products and research.
The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no significant geographic diversification reported. This concentration increases the risk associated with market fluctuations or regulatory changes in the primary operating region.
Looking ahead, the company's growth trajectory is uncertain. The current fiscal year is expected to show a decline in revenue, with no clear indication of a turnaround in the next fiscal year. The operating cash flow of -JPY 3.17 billion and free cash flow of -JPY 2.12 billion indicate ongoing cash burn, which could limit the company's ability to invest in research and development or expand its product portfolio.
Risk factors include the company's high debt load and negative cash flow, which could lead to liquidity constraints. The dilution potential is currently rated as low, but the company's financial performance and capital structure may change if it needs to raise additional funds through equity issuance.
Recent events, as reflected in the company's latest financial filings, include a significant net loss and a negative operating cash flow. These developments have led to a wide range of analyst price targets, from JPY 510 to JPY 1,130, with a mean recommendation of 2.00, indicating a generally positive outlook despite the current financial challenges.
- The company is operating at a net loss with a negative return on equity and assets, indicating poor profitability.
- The company's liquidity position is medium, with a negative net cash position after accounting for total debt.
- The company's revenue is concentrated in a single business segment, increasing exposure to market and regulatory risks.
- Analysts have a generally positive outlook, with a mean price target significantly higher than the current market price.
- The company's capital structure is heavily leveraged, with a debt-to-equity ratio of 1.5.
- margin_outlook_rationale: The company's margin outlook is negative due to ongoing losses and a lack of improvement in gross and operating margins.
- rd_outlook_rationale: The company's R&D outlook is uncertain, as it is currently burning cash and may not have sufficient funds to sustain long-term research initiatives.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | -35,68 |
| Revenue | —no estimate | —no estimate | 1,4B JPY |
| Operating income | —no estimate | —no estimate | —no estimate |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Return On Equitynet_income / total_equity
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- Ev To Revenueenterprise_value / revenue
- 4593.T Market data — financials · 2026-05-26
- Healios KK Market data — analyst estimates · 2026-05-26